211 related articles for article (PubMed ID: 35120067)
21. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.
Savinkina A; Madushani RWMA; Eftekhari Yazdi G; Wang J; Barocas JA; Morgan JR; Assoumou SA; Walley AY; Linas BP; Murphy SM
Addiction; 2022 Sep; 117(9):2450-2461. PubMed ID: 35315162
[TBL] [Abstract][Full Text] [Related]
22. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
[TBL] [Abstract][Full Text] [Related]
23. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
[TBL] [Abstract][Full Text] [Related]
24. Buprenorphine Dispensing Among Youth Aged ≤19 Years in the United States: 2015-2020.
Terranella A; Guy GP; Mikosz C
Pediatrics; 2023 Feb; 151(2):. PubMed ID: 36691760
[TBL] [Abstract][Full Text] [Related]
25. Predictors of availability of long-acting medication for opioid use disorder.
Shover CL; Humphreys K
Drug Alcohol Depend; 2019 Nov; 204():107586. PubMed ID: 31593871
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
27. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
[TBL] [Abstract][Full Text] [Related]
28. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
Andraka-Christou B; Saloner B; Gordon AJ; Totaram R; Randall-Kosich O; Golan M; Stein BD
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):492-503. PubMed ID: 35772010
[No Abstract] [Full Text] [Related]
29. Drug court utilization of medications for opioid use disorder in high opioid mortality communities.
Marlowe DB; Theiss DS; Ostlie EM; Carnevale J
J Subst Abuse Treat; 2022 Oct; 141():108850. PubMed ID: 35931014
[TBL] [Abstract][Full Text] [Related]
30. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
[TBL] [Abstract][Full Text] [Related]
31. Using machine learning to study the effect of medication adherence in Opioid Use Disorder.
Warren D; Marashi A; Siddiqui A; Eijaz AA; Pradhan P; Lim D; Call G; Dras M
PLoS One; 2022; 17(12):e0278988. PubMed ID: 36520864
[TBL] [Abstract][Full Text] [Related]
32. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
34. Treatment preference for opioid use disorder among people who are incarcerated.
Kaplowitz E; Truong AQ; Berk J; Martin RA; Clarke JG; Wieck M; Rich J; Brinkley-Rubinstein L
J Subst Abuse Treat; 2022 Jun; 137():108690. PubMed ID: 34930575
[TBL] [Abstract][Full Text] [Related]
35. Developing a cascade of care for opioid use disorder among individuals in jail.
Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
[TBL] [Abstract][Full Text] [Related]
36. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.
Klemperer EM; Wreschnig L; Crocker A; King-Mohr J; Ramniceanu A; Brooklyn JR; Peck KR; Rawson RA; Evans EA
J Subst Use Addict Treat; 2023 Sep; 152():209103. PubMed ID: 37311520
[TBL] [Abstract][Full Text] [Related]
37. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
38. Changes In County-Level Access To Medications For Opioid Use Disorder After Medicare Coverage Of Methadone Treatment Began.
Harris SJ; Yarbrough CR; Abraham AJ
Health Aff (Millwood); 2023 Jul; 42(7):991-996. PubMed ID: 37406230
[TBL] [Abstract][Full Text] [Related]
39. Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample.
Krawczyk N; Garrett B; Ahmad NJ; Patel E; Solomon K; Stuart EA; Saloner B
Drug Alcohol Depend; 2021 Mar; 220():108512. PubMed ID: 33508692
[TBL] [Abstract][Full Text] [Related]
40. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]